Status:
COMPLETED
Non-interventional Study on Time to Response and Quality of Life in Relapsed/Refractory Multiple Myeloma When Treated With Lenalidomide in Second Line
Lead Sponsor:
Hareth Nahi
Conditions:
Multiple Myeloma
Eligibility:
All Genders
18+ years
Brief Summary
The purpose of this study is to quantify the burden of treatment in relapsed or refractory multiple myeloma in patients receiving lenalidomide after one prior treatment for myeloma.
Eligibility Criteria
Inclusion
- Be at least 18 years of age
- Have a confirmed diagnosis of MM
- Starting lenalidomide treatment for MM (due to relapsed or refractory disease) after one prior treatment.
- Have personally signed and dated a legally effective written informed consent form prior to admission to the study.
- Must be willing and able to understand and comply with the study requirements.
Exclusion
- Individuals who have taken any experimental drugs or participated in a clinical trial within 30 days prior to screening.
- Individuals with significant psychiatric illness or a clinically significant acute/chronic uncontrolled medical condition that might affect their experience of myeloma symptoms or their ability to describe them.
Key Trial Info
Start Date :
November 1 2010
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
Estimated Enrollment :
133 Patients enrolled
Trial Details
Trial ID
NCT01430546
Start Date
November 1 2010
Last Update
March 25 2016
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Karolinska Institute
Stockholm, Sweden, S-141 86